Cat Media Pty Ltd - Keputusan Carian

Cuba - Sepanyol - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

genfibrozilo 600 mg

halewood laboratories pvt. ltd. - genfibrozilo - tableta revestida - 600 mg

Kesatuan Eropah - Sepanyol - EMA (European Medicines Agency)

brukinsa

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - agentes antineoplásicos - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Cuba - Sepanyol - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

enzalutamida 40 mg

lotus pharmaceuticals co. ltd - enzalutamida - cápsula blanda - 40 mg

Kesatuan Eropah - Sepanyol - EMA (European Medicines Agency)

sugammadex adroiq

extrovis eu ltd. - sugammadex sodium - bloqueo neuromuscular - todos los demás productos terapéuticos - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Kesatuan Eropah - Sepanyol - EMA (European Medicines Agency)

lacosamide adroiq

extrovis eu ltd. - lacosamida - epilepsia - los antiepilépticos, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.